These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
126 related articles for article (PubMed ID: 3541048)
1. Positron emission tomography and the possible origins of cytopathology in Alzheimer's disease. McGeer PL; McGeer EG; Kamo H; Wong K Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):501-18. PubMed ID: 3541048 [TBL] [Abstract][Full Text] [Related]
2. The 12th J. A. F. Stevenson memorial lecture. Aging, Alzheimer's disease, and the cholinergic system. McGeer PL Can J Physiol Pharmacol; 1984 Jul; 62(7):741-54. PubMed ID: 6149804 [TBL] [Abstract][Full Text] [Related]
3. Longitudinal PET Evaluation of Cerebral Metabolic Decline in Dementia: A Potential Outcome Measure in Alzheimer's Disease Treatment Studies. Alexander GE; Chen K; Pietrini P; Rapoport SI; Reiman EM Am J Psychiatry; 2002 May; 159(5):738-45. PubMed ID: 11986126 [TBL] [Abstract][Full Text] [Related]
4. Neocortical and hippocampal glucose hypometabolism following neurotoxic lesions of the entorhinal and perirhinal cortices in the non-human primate as shown by PET. Implications for Alzheimer's disease. Meguro K; Blaizot X; Kondoh Y; Le Mestric C; Baron JC; Chavoix C Brain; 1999 Aug; 122 ( Pt 8)():1519-31. PubMed ID: 10430835 [TBL] [Abstract][Full Text] [Related]
5. Cortical metabolism, acetylcholinesterase staining and pathological changes in Alzheimer's disease. McGeer EG; McGeer PL; Kamo H; Tago H; Harrop R Can J Neurol Sci; 1986 Nov; 13(4 Suppl):511-6. PubMed ID: 2431752 [TBL] [Abstract][Full Text] [Related]
6. Declining brain activity in cognitively normal apolipoprotein E epsilon 4 heterozygotes: A foundation for using positron emission tomography to efficiently test treatments to prevent Alzheimer's disease. Reiman EM; Caselli RJ; Chen K; Alexander GE; Bandy D; Frost J Proc Natl Acad Sci U S A; 2001 Mar; 98(6):3334-9. PubMed ID: 11248079 [TBL] [Abstract][Full Text] [Related]
7. Age- and Brain Region-Specific Changes of Glucose Metabolic Disorder, Learning, and Memory Dysfunction in Early Alzheimer's Disease Assessed in APP/PS1 Transgenic Mice Using Li XY; Men WW; Zhu H; Lei JF; Zuo FX; Wang ZJ; Zhu ZH; Bao XJ; Wang RZ Int J Mol Sci; 2016 Oct; 17(10):. PubMed ID: 27763550 [TBL] [Abstract][Full Text] [Related]
8. Effect of piracetam on cerebral glucose metabolism in Alzheimer's disease as measured by positron emission tomography. Heiss WD; Hebold I; Klinkhammer P; Ziffling P; Szelies B; Pawlik G; Herholz K J Cereb Blood Flow Metab; 1988 Aug; 8(4):613-7. PubMed ID: 3260597 [TBL] [Abstract][Full Text] [Related]
9. Metabolic reduction in the posterior cingulate cortex in very early Alzheimer's disease. Minoshima S; Giordani B; Berent S; Frey KA; Foster NL; Kuhl DE Ann Neurol; 1997 Jul; 42(1):85-94. PubMed ID: 9225689 [TBL] [Abstract][Full Text] [Related]
11. The neurometabolic landscape of cognitive decline: in vivo studies with positron emission tomography in Alzheimer's disease. Pietrini P; Alexander GE; Furey ML; Hampel H; Guazzelli M Int J Psychophysiol; 2000 Jul; 37(1):87-98. PubMed ID: 10828377 [TBL] [Abstract][Full Text] [Related]
12. Positron emission tomography in patients with clinically diagnosed Alzheimer's disease. McGeer PL; Kamo H; Harrop R; Li DK; Tuokko H; McGeer EG; Adam MJ; Ammann W; Beattie BL; Calne DB CMAJ; 1986 Mar; 134(6):597-607. PubMed ID: 3512063 [TBL] [Abstract][Full Text] [Related]
13. Preferential metabolic involvement of visual cortical areas in a subtype of Alzheimer's disease: clinical implications. Pietrini P; Furey ML; Graff-Radford N; Freo U; Alexander GE; Grady CL; Dani A; Mentis MJ; Schapiro MB Am J Psychiatry; 1996 Oct; 153(10):1261-8. PubMed ID: 8831432 [TBL] [Abstract][Full Text] [Related]
14. Cerebral metabolism as measured with positron emission tomography (PET) and [18F] 2-deoxy-D-glucose: healthy aging, Alzheimer's disease and Down syndrome. Cutler NR Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):309-21. PubMed ID: 2948218 [TBL] [Abstract][Full Text] [Related]
15. Regional cerebral glucose metabolism in dementia with Lewy bodies and Alzheimer's disease: a comparative study using positron emission tomography. Imamura T; Ishii K; Sasaki M; Kitagaki H; Yamaji S; Hirono N; Shimomura T; Hashimoto M; Tanimukai S; Kazui H; Mori E Neurosci Lett; 1997 Oct; 235(1-2):49-52. PubMed ID: 9389593 [TBL] [Abstract][Full Text] [Related]
16. The functional neuroanatomy of verbal memory in Alzheimer's disease: [ Staffaroni AM; Melrose RJ; Leskin LP; Riskin-Jones H; Harwood D; Mandelkern M; Sultzer DL J Clin Exp Neuropsychol; 2017 Sep; 39(7):682-693. PubMed ID: 27876444 [TBL] [Abstract][Full Text] [Related]
17. Longitudinal influence of microglial activation and amyloid on neuronal function in Alzheimer's disease. Fan Z; Okello AA; Brooks DJ; Edison P Brain; 2015 Dec; 138(Pt 12):3685-98. PubMed ID: 26510952 [TBL] [Abstract][Full Text] [Related]
18. Low glucose metabolism during brain stimulation in older Down's syndrome subjects at risk for Alzheimer's disease prior to dementia. Pietrini P; Dani A; Furey ML; Alexander GE; Freo U; Grady CL; Mentis MJ; Mangot D; Simon EW; Horwitz B; Haxby JV; Schapiro MB Am J Psychiatry; 1997 Aug; 154(8):1063-9. PubMed ID: 9247390 [TBL] [Abstract][Full Text] [Related]
19. Abnormalities of regional brain metabolism in Alzheimer's disease and their relation to functional impairment. Haxby JV; Rapoport SI Prog Neuropsychopharmacol Biol Psychiatry; 1986; 10(3-5):427-38. PubMed ID: 3541045 [TBL] [Abstract][Full Text] [Related]
20. Alterations in α4β2 nicotinic receptors in cognitive decline in Alzheimer's aetiopathology. Okada H; Ouchi Y; Ogawa M; Futatsubashi M; Saito Y; Yoshikawa E; Terada T; Oboshi Y; Tsukada H; Ueki T; Watanabe M; Yamashita T; Magata Y Brain; 2013 Oct; 136(Pt 10):3004-17. PubMed ID: 23975517 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]